Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003066651 | SCV003444820 | uncertain significance | Tay-Sachs disease | 2024-01-22 | criteria provided, single submitter | clinical testing | This sequence change replaces alanine, which is neutral and non-polar, with glycine, which is neutral and non-polar, at codon 496 of the HEXA protein (p.Ala496Gly). This variant is present in population databases (rs373781108, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with HEXA-related conditions. ClinVar contains an entry for this variant (Variation ID: 2139666). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt HEXA protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV003066652 | SCV003532214 | uncertain significance | Inborn genetic diseases | 2023-12-02 | criteria provided, single submitter | clinical testing | The p.A496G variant (also known as c.1487C>G), located in coding exon 13 of the HEXA gene, results from a C to G substitution at nucleotide position 1487. The alanine at codon 496 is replaced by glycine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV003481372 | SCV004227441 | uncertain significance | not provided | 2022-12-08 | criteria provided, single submitter | clinical testing | PP3, PM3 |